Clinical features and treatment outcomes of limited-stage mantle cell lymphoma: Consortium for Improving Survival of Lymphoma report

and Consortium for Improving Survival of Lymphoma (CISL)

Research output: Contribution to journalArticle

Abstract

Limited-stage (Ann Arbor stage I or II) mantle cell lymphoma (MCL) is an extremely rare disease. Thus, there is little data on the clinical features and treatment outcomes of patients with early-stage MCL. We examined consecutive stage I or II MCL 41 cases diagnosed between 2000 and 2016 in 16 institutions of the Consortium for Improving Survival of Lymphoma group. All cases were pathologically confirmed and systemic evaluation was performed for staging. The clinical features were reviewed, and the treatment outcomes were analyzed. The median age of patients was 66 years (range 19–85 years); there were more men (n = 31, 75.6%) than women. Most patients (n = 28, 68.3%) had stage 2 disease, and 29 (70.7%) were symptomatic. The elevation of lactate dehydrogenase (n = 2, 4.9%) was not common; thus, 39 patients (95.1%) had a low-risk score (0 or 1) for the International Prognostic Index, and 28 (68.3%) had a low-risk score (1–3) for the MCL International Prognostic Index. Most patients (n = 37, 90.1%) received chemotherapy as the first therapeutic strategy, while some received radiotherapy (n = 2), surgical resection (n = 1), or no treatment (n = 1). Of the patients who received chemotherapy, 23 (56.9%) received a rituximab-containing regimen, and R-CHOP (n = 17) and R-bendamustine (n = 5) were commonly used. The best response was noted in 97.4% (n = 38) of patients, including 32 who showed a complete response (78%). With a median follow-up duration of 40.6 months, the 42 months relapse-free survival was 59.1%, and the 5-year overall survival rate was 80.4%. Limited-state MCL showed indolent clinical and low-risk prognostic features. Chemotherapy could be effective for controlling localized MCL lesions, with high complete response rates.

Original languageEnglish
Pages (from-to)223-228
Number of pages6
JournalAnnals of Hematology
Volume99
Issue number2
DOIs
Publication statusPublished - 2020 Feb 1

Fingerprint

Mantle-Cell Lymphoma
Lymphoma
Survival
Drug Therapy
Rare Diseases
Radiotherapy
Survival Rate
Recurrence
Therapeutics

Keywords

  • Limited stage
  • Mantle cell lymphoma
  • Prognosis

ASJC Scopus subject areas

  • Hematology

Cite this

Clinical features and treatment outcomes of limited-stage mantle cell lymphoma : Consortium for Improving Survival of Lymphoma report. / and Consortium for Improving Survival of Lymphoma (CISL).

In: Annals of Hematology, Vol. 99, No. 2, 01.02.2020, p. 223-228.

Research output: Contribution to journalArticle

and Consortium for Improving Survival of Lymphoma (CISL). / Clinical features and treatment outcomes of limited-stage mantle cell lymphoma : Consortium for Improving Survival of Lymphoma report. In: Annals of Hematology. 2020 ; Vol. 99, No. 2. pp. 223-228.
@article{e3a71623a6a0483c88af35b007957729,
title = "Clinical features and treatment outcomes of limited-stage mantle cell lymphoma: Consortium for Improving Survival of Lymphoma report",
abstract = "Limited-stage (Ann Arbor stage I or II) mantle cell lymphoma (MCL) is an extremely rare disease. Thus, there is little data on the clinical features and treatment outcomes of patients with early-stage MCL. We examined consecutive stage I or II MCL 41 cases diagnosed between 2000 and 2016 in 16 institutions of the Consortium for Improving Survival of Lymphoma group. All cases were pathologically confirmed and systemic evaluation was performed for staging. The clinical features were reviewed, and the treatment outcomes were analyzed. The median age of patients was 66 years (range 19–85 years); there were more men (n = 31, 75.6{\%}) than women. Most patients (n = 28, 68.3{\%}) had stage 2 disease, and 29 (70.7{\%}) were symptomatic. The elevation of lactate dehydrogenase (n = 2, 4.9{\%}) was not common; thus, 39 patients (95.1{\%}) had a low-risk score (0 or 1) for the International Prognostic Index, and 28 (68.3{\%}) had a low-risk score (1–3) for the MCL International Prognostic Index. Most patients (n = 37, 90.1{\%}) received chemotherapy as the first therapeutic strategy, while some received radiotherapy (n = 2), surgical resection (n = 1), or no treatment (n = 1). Of the patients who received chemotherapy, 23 (56.9{\%}) received a rituximab-containing regimen, and R-CHOP (n = 17) and R-bendamustine (n = 5) were commonly used. The best response was noted in 97.4{\%} (n = 38) of patients, including 32 who showed a complete response (78{\%}). With a median follow-up duration of 40.6 months, the 42 months relapse-free survival was 59.1{\%}, and the 5-year overall survival rate was 80.4{\%}. Limited-state MCL showed indolent clinical and low-risk prognostic features. Chemotherapy could be effective for controlling localized MCL lesions, with high complete response rates.",
keywords = "Limited stage, Mantle cell lymphoma, Prognosis",
author = "{and Consortium for Improving Survival of Lymphoma (CISL)} and Jo, {Jae Cheol} and Kim, {Seok Jin} and Lee, {Ho Sup} and Eom, {Hyeon Seok} and Lee, {Soon Il} and Yong Park and Lee, {Jeong Ok} and Yoojin Lee and Yhim, {Ho Young} and Yang, {Deok Hwan} and Byun, {Ja Min} and Kang, {Hye Jin} and Kim, {Hyo Jung} and Shin, {Ho Jin} and Yoo, {Kwai Han} and Cheolwon Suh",
year = "2020",
month = "2",
day = "1",
doi = "10.1007/s00277-019-03803-x",
language = "English",
volume = "99",
pages = "223--228",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Clinical features and treatment outcomes of limited-stage mantle cell lymphoma

T2 - Consortium for Improving Survival of Lymphoma report

AU - and Consortium for Improving Survival of Lymphoma (CISL)

AU - Jo, Jae Cheol

AU - Kim, Seok Jin

AU - Lee, Ho Sup

AU - Eom, Hyeon Seok

AU - Lee, Soon Il

AU - Park, Yong

AU - Lee, Jeong Ok

AU - Lee, Yoojin

AU - Yhim, Ho Young

AU - Yang, Deok Hwan

AU - Byun, Ja Min

AU - Kang, Hye Jin

AU - Kim, Hyo Jung

AU - Shin, Ho Jin

AU - Yoo, Kwai Han

AU - Suh, Cheolwon

PY - 2020/2/1

Y1 - 2020/2/1

N2 - Limited-stage (Ann Arbor stage I or II) mantle cell lymphoma (MCL) is an extremely rare disease. Thus, there is little data on the clinical features and treatment outcomes of patients with early-stage MCL. We examined consecutive stage I or II MCL 41 cases diagnosed between 2000 and 2016 in 16 institutions of the Consortium for Improving Survival of Lymphoma group. All cases were pathologically confirmed and systemic evaluation was performed for staging. The clinical features were reviewed, and the treatment outcomes were analyzed. The median age of patients was 66 years (range 19–85 years); there were more men (n = 31, 75.6%) than women. Most patients (n = 28, 68.3%) had stage 2 disease, and 29 (70.7%) were symptomatic. The elevation of lactate dehydrogenase (n = 2, 4.9%) was not common; thus, 39 patients (95.1%) had a low-risk score (0 or 1) for the International Prognostic Index, and 28 (68.3%) had a low-risk score (1–3) for the MCL International Prognostic Index. Most patients (n = 37, 90.1%) received chemotherapy as the first therapeutic strategy, while some received radiotherapy (n = 2), surgical resection (n = 1), or no treatment (n = 1). Of the patients who received chemotherapy, 23 (56.9%) received a rituximab-containing regimen, and R-CHOP (n = 17) and R-bendamustine (n = 5) were commonly used. The best response was noted in 97.4% (n = 38) of patients, including 32 who showed a complete response (78%). With a median follow-up duration of 40.6 months, the 42 months relapse-free survival was 59.1%, and the 5-year overall survival rate was 80.4%. Limited-state MCL showed indolent clinical and low-risk prognostic features. Chemotherapy could be effective for controlling localized MCL lesions, with high complete response rates.

AB - Limited-stage (Ann Arbor stage I or II) mantle cell lymphoma (MCL) is an extremely rare disease. Thus, there is little data on the clinical features and treatment outcomes of patients with early-stage MCL. We examined consecutive stage I or II MCL 41 cases diagnosed between 2000 and 2016 in 16 institutions of the Consortium for Improving Survival of Lymphoma group. All cases were pathologically confirmed and systemic evaluation was performed for staging. The clinical features were reviewed, and the treatment outcomes were analyzed. The median age of patients was 66 years (range 19–85 years); there were more men (n = 31, 75.6%) than women. Most patients (n = 28, 68.3%) had stage 2 disease, and 29 (70.7%) were symptomatic. The elevation of lactate dehydrogenase (n = 2, 4.9%) was not common; thus, 39 patients (95.1%) had a low-risk score (0 or 1) for the International Prognostic Index, and 28 (68.3%) had a low-risk score (1–3) for the MCL International Prognostic Index. Most patients (n = 37, 90.1%) received chemotherapy as the first therapeutic strategy, while some received radiotherapy (n = 2), surgical resection (n = 1), or no treatment (n = 1). Of the patients who received chemotherapy, 23 (56.9%) received a rituximab-containing regimen, and R-CHOP (n = 17) and R-bendamustine (n = 5) were commonly used. The best response was noted in 97.4% (n = 38) of patients, including 32 who showed a complete response (78%). With a median follow-up duration of 40.6 months, the 42 months relapse-free survival was 59.1%, and the 5-year overall survival rate was 80.4%. Limited-state MCL showed indolent clinical and low-risk prognostic features. Chemotherapy could be effective for controlling localized MCL lesions, with high complete response rates.

KW - Limited stage

KW - Mantle cell lymphoma

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=85076904513&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85076904513&partnerID=8YFLogxK

U2 - 10.1007/s00277-019-03803-x

DO - 10.1007/s00277-019-03803-x

M3 - Article

C2 - 31853704

AN - SCOPUS:85076904513

VL - 99

SP - 223

EP - 228

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

IS - 2

ER -